InhA inhibitors (GlaxoSmithKline/The Global Alliance for TB Drug Development)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameInhA inhibitors (GlaxoSmithKline/The Global Alliance for TB Drug Development)
Drug Alias NameInhA inhibitors (GlaxoSmithKline/The Global Alliance for TB Drug Development)InhA inhibitors (GSK/TB Alliance)GSK-2231260A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEnoyl-acyl-carrier protein reductase inhibitors
TargetsEnoyl-acyl-carrier protein reductase
Therapy Area/IndicationsTuberculosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcTb Alliance
Active IndicationsN/A
Inactive IndicationsTuberculosis

Other Information

ATC CodeN/A
Related LinksN/A